Broadwood Partners buys STAAR Surgical (STAA) shares for $41 million

Broadwood Partners bought roughly $41.06 million of STAAR Surgical shares between Nov. 19–21, 2025—acquiring 1.50 million+ shares in three tranches and bringing its direct stake to 15,019,491 shares (Neal C. Bradsher holds 25,900 shares)—as STAAR reported preliminary Q3 revenue of $94.7 million, up 6.9% year‑over‑year and ahead of the $90.1 million consensus. The activity comes ahead of a Special Meeting to vote on Alcon’s proposed $28‑per‑share merger (a 59% premium to STAAR’s 90‑day VWAP) that STAAR’s board has unanimously recommended; Canaccord Genuity kept a Hold rating and $28 target, while 5.1% holder Yunqi Capital has voiced frustration over a delayed vote. STAAR also disputed Broadwood’s assertions of potential acquisition interest, saying other communications were merely introductory, leaving the shareholder vote as the key near‑term catalyst.

Analysis

Broadwood Partners purchased a total of $41,060,317 of STAAR Surgical (NASDAQ: STAA) stock across three tranches from Nov. 19–21, 2025—309,132 shares at a weighted average of $26.4164 on Nov. 19, 393,382 shares at $27.1373 on Nov. 20, and 797,486 shares at $27.8611 on Nov. 21—bringing its direct holding to 15,019,491 shares; Neal C. Bradsher directly holds 25,900 shares. STAAR reported preliminary Q3 revenue of $94.7 million, a 6.9% year-over-year increase that beat the $90.1 million analyst consensus, and Canaccord Genuity maintained a Hold rating with a $28 price target after the update.

Alcon’s proposed merger values STAAR at $28 per share, which the article notes represents a 59% premium to STAAR’s 90‑day VWAP and has unanimous support from STAAR’s board; a Special Meeting of Stockholders is scheduled to vote on the transaction. Activist and shareholder dynamics are in play: 5.1% holder Yunqi Capital publicly criticized a delay in the vote, Broadwood’s purchases prompted claims of acquisition interest that STAAR has disputed as merely introductory, and these developments make the shareholder vote the primary near‑term catalyst.

The combination of a revenue beat and a board‑backed $28 offer suggests limited upside for STAA absent a higher bid or renegotiation, consistent with Canaccord’s $28 target, while the shareholder dispute and voting delay create execution and timing risk that could produce short-term volatility. Market sentiment in the article is moderately positive but conditional on the vote outcome and any further activist or bidder moves, so monitoring the Special Meeting, communications from Broadwood and Yunqi, and any new bid-related disclosures will be decisive for the stock’s trajectory.

Key Decisions for Investors

• Investors should treat $28 as the de facto near‑term value floor given the board‑recommended Alcon offer and Canaccord’s unchanged $28 target and avoid initiating large new long positions above that level
• It may be prudent to hold existing positions if exposure is for deal completion, but consider trimming or hedging near-term exposure because Yunqi Capital’s public frustration and the delayed shareholder vote raise execution and timing risk
• Monitor the Special Meeting date, any formal statements from Broadwood Partners or Yunqi Capital, and any revised bids or due diligence disclosures—if a competing bidder or higher offer emerges, reassess upside; if not, prioritize downside protection
• Consider short‑dated protective puts or collars to limit downside through the vote window rather than outright selling if tax or liquidity considerations apply